Quince therapeutics appoints former reata pharmaceuticals chief r&d officer dr. rajiv patni to its board of directors

South san francisco, calif.--(business wire)---- $qncx--quince therapeutics, inc. (nasdaq: qncx), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient's own biology to deliver rare disease therapeutics, today announced the appointment of rajiv patni, m.d., a biopharma industry veteran and global product development expert, to the company's board of directors. “we are pleased to welcome a proven clinical development leader of dr. rajiv patni's calib.
QNCX Ratings Summary
QNCX Quant Ranking